Drug Trial Radar · NCT06903286
Extension Study of Participants From SPG302-ALS-001
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
May 29, 2025
Primary completion
Jun 30, 2025
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- SpinogenixIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
SPG302Drug
Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events and serious adverse eventsTime frame: Up to 52 weeks
- C-SSRS (Columbia Suicide Severity Rating Scale)Time frame: Up to 52 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Macquarie University
North Ryde, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Flinders Medical Center
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.